Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LTH001
MIFTS: 38

Lethal Midline Granuloma

Categories: Rare diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lethal Midline Granuloma

About this section

MalaCards integrated aliases for Lethal Midline Granuloma:

Name: Lethal Midline Granuloma 12 15
Granuloma, Lethal Midline 44 73
Midfacial Necrotising Lesion 12
Malignant Granuloma of Face 12
Midline Lethal Granuloma 53

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Respiratory diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:9072
ICD10 33 M31.2
ICD9CM 35 446.3
MeSH 44 D006103
NCIt 50 C8196
SNOMED-CT 68 58961005
UMLS 73 C0018197
Sources

Summaries for Lethal Midline Granuloma

About this section
MalaCards based summary : Lethal Midline Granuloma, also known as granuloma, lethal midline, is related to peripheral t-cell lymphoma and extranodal nasal nk/t cell lymphoma. An important gene associated with Lethal Midline Granuloma is ICAM1 (Intercellular Adhesion Molecule 1), and among its related pathways/superpathways are Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell and L1CAM interactions. The drugs Dexamethasone acetate and Pegaspargase have been mentioned in the context of this disorder. Affiliated tissues include t cells, colon and nk cells, and related phenotype is Negative genetic interaction between MUS81-/- and MUS81+/+.

Wikipedia : 76 Lethal midline granuloma is a condition affecting the nose and palate. The preferred modern term is... more...

Sources

Related Diseases for Lethal Midline Granuloma

About this section

Diseases related to Lethal Midline Granuloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 27)
# Related Disease Score Top Affiliating Genes
1 peripheral t-cell lymphoma 29.8 NCAM1 TIA1
2 extranodal nasal nk/t cell lymphoma 11.9
3 lymphoma 10.6
4 polymorphic reticulosis 10.3
5 histiocytosis 10.3
6 malignant histiocytosis 10.3
7 lymphomatoid granulomatosis 10.2
8 cortical thymoma 10.1 CD2 ICAM1
9 actinic prurigo 10.1 CD2 ICAM1
10 pericoronitis 10.0 CD2 NCAM1
11 autoimmune lymphoproliferative syndrome, type v 10.0
12 lymphosarcoma 10.0
13 lymphomatoid papulosis 10.0
14 lepromatous leprosy 10.0 CD2 ICAM1
15 intestine carcinoma in situ 10.0 ICAM1 NCAM1
16 chronic nk-cell lymphocytosis 10.0 CD2 NCAM1
17 colon carcinoma in situ 9.9 ICAM1 NCAM1
18 t-cell adult acute lymphocytic leukemia 9.9 CD2 TIA1
19 orbit lymphoma 9.9 NCAM1 TIA1
20 parasitic ichthyosporea infectious disease 9.9 NCAM1 TIA1
21 rhinosporidiosis 9.9 NCAM1 TIA1
22 subcutaneous panniculitis-like t-cell lymphoma 9.9 NCAM1 TIA1
23 leukocyte disease 9.9 CD2 NCAM1
24 panniculitis 9.8 NCAM1 TIA1
25 ileum cancer 9.8 NCAM1 TIA1
26 natural killer cell leukemia 9.7 CD2 NCAM1 TIA1
27 lymphatic system cancer 9.7 CD2 NCAM1 TIA1

Graphical network of the top 20 diseases related to Lethal Midline Granuloma:



Diseases related to Lethal Midline Granuloma
Sources

Symptoms & Phenotypes for Lethal Midline Granuloma

About this section

GenomeRNAi Phenotypes related to Lethal Midline Granuloma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Negative genetic interaction between MUS81-/- and MUS81+/+ GR00255-A-2 8.8 CD2 ICAM1 LILRA3
Sources

Drugs & Therapeutics for Lethal Midline Granuloma

About this section

Drugs for Lethal Midline Granuloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 257)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1177-87-3
2
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 130167-69-0
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
5
Mesna Approved, Investigational Phase 4,Phase 2 3375-50-6 598
6
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
7
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
8
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
9
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-05-2, 1959-05-2 126941
10
Mechlorethamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-75-2 4033
11 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15
Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 0
16 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
22 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
24 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
25 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
26 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
27
asparaginase Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
30 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
32 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 N-Methylaspartate Phase 4,Phase 2
38 Aspartic Acid Phase 4,Phase 2
39 Protective Agents Phase 4,Phase 2,Phase 1,Not Applicable
40
Doxorubicin Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 23214-92-8 31703
41
alemtuzumab Approved, Investigational Phase 3,Phase 2 216503-57-0
42
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
43
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
44
Levoleucovorin Approved, Investigational Phase 3,Not Applicable 68538-85-2
45
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
46 Orange Approved Phase 3
47
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
48
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
49
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
50
Iron Approved Phase 3,Phase 2,Phase 1 7439-89-6 23925

Interventional clinical trials:

(show top 50) (show all 209)
# Name Status NCT ID Phase Drugs
1 Treatment of Natural Killer/T Cell Lymphoma-I/II Recruiting NCT01501136 Phase 4
2 Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ Recruiting NCT01501149 Phase 4 DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase);Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）
3 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
4 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Unknown status NCT00725231 Phase 3 chemotherapy
5 PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma Unknown status NCT02085655 Phase 3 pegaspargase;Gemcitabine;Oxaliplatin;Methotrexate;Dexamethasone;Thalidomide
6 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
7 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
8 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
9 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
10 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
11 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
12 MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma Recruiting NCT02631239 Phase 3 Methotrexate;Etoposide;Dexamethasone;Pegaspargase
13 PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage Recruiting NCT02918747 Phase 3 pegaspargase;Gemcitabine;Oxaliplatin;Dexamethasone;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone
14 SIMPLE Chemotherapy for NK Lymphoma/Leukaemia Recruiting NCT03623087 Phase 3 Cisplatin;Gemcitabine;Etoposide (VP-16);Dexamethasone;L-asparaginase
15 Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage Terminated NCT02359162 Phase 3 Gemcitabine;Oxaliplatin;Pegaspargase;Etoposide;Vincristine;Doxorubicin;Cyclophosphamide;Prednisone
16 Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma Unknown status NCT01667302 Phase 2 Radiotherapy followed by chemotherapy
17 Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell Lymphoma Unknown status NCT01007526 Phase 2
18 New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell Lymphoma Unknown status NCT00933673 Phase 2 L-asp, DXM, IFO, VP-16, DDP
19 Study on the Combination Regimen of Dexamethasone Ifosfamide Cisplatin Etoposide in Patients With NK/T Cell Lymphoma Unknown status NCT00568607 Phase 2 IFO, VP-16, DDP, DXM
20 MESA Treatment for NK/T Cell Lymphoma Unknown status NCT01933282 Phase 2 MESA chemotherapy;MESA
21 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
22 CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
23 Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer Unknown status NCT00387530 Phase 2 oral sodium phenylbutyrate;valganciclovir
24 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
25 Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma Completed NCT02825147 Phase 2 Pegaspargase;Methotrexate;Dexamethasone;Etoposide
26 Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma Completed NCT00901147 Phase 2 panobinostat and bortezomib
27 L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma Completed NCT00854425 Phase 2 L-asparaginase
28 Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma Completed NCT01238159 Phase 2
29 A Phase II Study of Nasal NK/T-cell Lymphoma Completed NCT00292695 Phase 2
30 Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma Completed NCT00418535 Phase 2 Concurrent Radiotherapy (RT)/cisplatin, VIPD
31 Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma Completed NCT02276248 Phase 2 GDP chemotherapy
32 Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas Completed NCT00374699 Phase 1, Phase 2 Velcade
33 Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas Completed NCT02280785 Phase 2 Brentuximab vedotin
34 Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma Completed NCT00283985 Phase 2 Kidrolase;Methotrexate;Dexamethasone;Erwinase
35 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
36 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
37 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
38 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
39 Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2 Alisertib
40 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
41 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
42 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
43 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
44 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
45 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
46 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
47 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
48 Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer Completed NCT00787761 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
49 Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00611351 Phase 2 busulfan;cyclophosphamide;mycophenolate mofetil;tacrolimus
50 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa

Search NIH Clinical Center for Lethal Midline Granuloma

Cochrane evidence based reviews: granuloma, lethal midline

Sources

Genetic Tests for Lethal Midline Granuloma

About this section
Sources

Anatomical Context for Lethal Midline Granuloma

About this section

MalaCards organs/tissues related to Lethal Midline Granuloma:

41
T Cells, Colon, Nk Cells
Sources

Publications for Lethal Midline Granuloma

About this section

Articles related to Lethal Midline Granuloma:

(show top 50) (show all 76)
# Title Authors Year
1
Lethal midline granuloma. ( 23440011 )
2013
2
Mucor irregularis infection and lethal midline granuloma: a case report and review of published literature. ( 22744721 )
2012
3
Nasal NK/T cell lymphoma presenting as a lethal midline granuloma. ( 18388376 )
2008
4
Lethal midline granuloma: a case of T-cell lymphoma. ( 18043881 )
2007
5
Prosthetic rehabilitation of a midfacial defect resulting from lethal midline granuloma--a clinical report. ( 17002746 )
2006
6
Lethal midline granuloma-nasal natural killer/T-cell lymphoma. ( 16601443 )
2006
7
Lethal midline granuloma in a human immunodeficiency virus-infected patient. ( 11545099 )
2001
8
Lethal midline granuloma: report of three cases. ( 10835805 )
2000
9
Lethal midline granuloma starting as granuloma laryngis. ( 10778778 )
2000
10
Nasal natural killer cell lymphoma presenting as lethal midline granuloma. ( 11168665 )
2000
11
Lethal midline granuloma revisited: nasal T/Natural-killer cell lymphoma. ( 10561195 )
1999
12
Treatment of localized non-Hodgkin's lymphomas of the head and neck: focusing on cases of non-lethal midline granuloma. ( 9727875 )
1998
13
Sinonasal lymphoma presenting as a lethal midline granuloma: case report. ( 9590351 )
1998
14
Angiocentric T-cell lymphoma presenting as lethal midline granuloma. ( 9248885 )
1997
15
Treatment of lethal midline granuloma type nasal T-cell lymphoma. ( 9208902 )
1997
16
Circulating intercellular adhesion molecule-1 and its cellular expression in head and neck non-Hodgkin's lymphomas, including lethal midline granuloma. ( 8712635 )
1996
17
Experience of radiotherapy in lethal midline granuloma with special emphasis on centrofacial T-cell lymphoma: a retrospective analysis covering a 34-year period. ( 8850419 )
1996
18
Nasal T-cell lymphoma and the lethal midline granuloma syndrome. ( 8643282 )
1996
19
Sinonasal T-cell lymphoma in the differential diagnosis of lethal midline granuloma using in situ hybridization for Epstein-Barr virus RNA. ( 8821949 )
1996
20
A case of angiocentric T-cell lymphoma presenting as lethal midline granuloma. ( 8573935 )
1995
21
Aggressive natural killer cell leukaemia/lymphoma in two patients with lethal midline granuloma. ( 8043452 )
1994
22
Epstein-Barr virus in patients with polymorphic reticulosis (lethal midline granuloma) from China and Japan. ( 8200002 )
1994
23
Lethal midline granuloma in Okinawa with special emphasis on polymorphic reticulosis. ( 8200852 )
1994
24
Lethal midline granuloma: a case of Ki-1 lymphoma. ( 8191049 )
1993
25
Lethal midline granuloma in Seoul (Korea) and Shanghai (China) ( 1399151 )
1992
26
Fireside conference 19. Wegener's granulomatosis and lethal midline granuloma. ( 1389398 )
1992
27
Lethal midline granuloma (peripheral T-cell lymphoma) after lymphomatoid papulosis. ( 1322784 )
1992
28
Lethal midline granuloma: impact of imaging studies on the investigation and management of destructive mid facial disease in 13 patients. ( 1603316 )
1992
29
Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. ( 1967431 )
1990
30
Current concepts of the lethal midline granuloma syndrome. ( 2113254 )
1990
31
Current concepts of the lethal midline granuloma syndrome. ( 2501742 )
1989
32
Heterogeneous malignant non Hodgkin's lymphomas as a causative disorder in lethal midline granuloma. ( 2527438 )
1989
33
A clinicopathologic study of malignant lymphomas of the nose, paranasal sinuses, and hard palate, including cases of lethal midline granuloma. ( 2819661 )
1989
34
Lethal midline granuloma and lymphoproliferative disorders. ( 2769118 )
1989
35
Lymphomatoid granulomatosis--evidence of a clonal T-cell origin and an association with lethal midline granuloma. ( 2978432 )
1988
36
Computed tomography of lethal midline granuloma. 5 case reports. ( 3169024 )
1988
37
Peripheral T cell lymphoma presenting primarily as lethal midline granuloma. ( 3262084 )
1988
38
Lethal midline granuloma (polymorphic reticulosis) and lymphomatoid granulomatosis. Evidence for a monoclonal T-cell lymphoproliferative disorder. ( 3260812 )
1988
39
Lethal midline granuloma with a novel T-cell phenotype as found in peripheral T-cell lymphoma. ( 3493060 )
1987
40
Association of Epstein-Barr virus with lethal midline granuloma. ( 2995813 )
1985
41
Non-lethal midline granuloma of the nose. ( 7133645 )
1982
42
Nasal T-cell lymphoma as a type of so-called "lethal midline granuloma". ( 6754065 )
1982
43
Malignant histiocytosis presenting as lethal midline granuloma: immunohistological study. ( 6752361 )
1982
44
Biopsy findings in malignant histiocytosis presenting as lethal midline granuloma. ( 7085910 )
1982
45
Malignant histiocytosis presenting as lethal midline granuloma. ( 7279783 )
1981
46
Polymorphic reticulosis (lethal midline granuloma) and lymphomatoid granulomatosis: identical or distinct entities? ( 7281476 )
1981
47
Malignant lymphoma in the nose. Clinicopathological differences from the malignant histiocytosis presenting as lethal midline granuloma. ( 7312704 )
1981
48
The protean clinical features of polymorphic reticulosis (lethal midline granuloma). ( 933689 )
1976
49
Lethal midline granuloma: a pathological spectrum. ( 5566 )
1976
50
"Lethal midline granuloma". ( 959417 )
1976
Sources

Variations for Lethal Midline Granuloma

About this section
Sources

Expression for Lethal Midline Granuloma

About this section
Search GEO for disease gene expression data for Lethal Midline Granuloma.
Sources

Pathways for Lethal Midline Granuloma

About this section

Pathways related to Lethal Midline Granuloma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 66
11.45 ICAM1 LILRA3
2
L1CAM interactions 66
Show member pathways
 11.35 NCAM1 SPTAN1
3
Adhesion 4
11.25 ICAM1 NCAM1
4
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.02 CD2 NCAM1
5
Cell adhesion molecules (CAMs) 37
10.96 CD2 ICAM1 NCAM1
Sources

GO Terms for Lethal Midline Granuloma

About this section

Cellular components related to Lethal Midline Granuloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.13 CD2 ICAM1 NCAM1
2 external side of plasma membrane GO:0009897 8.8 CD2 ICAM1 NCAM1

Biological processes related to Lethal Midline Granuloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.33 CD2 ICAM1 NCAM1
2 cell-cell adhesion GO:0098609 9.26 CD2 ICAM1
3 viral entry into host cell GO:0046718 8.96 ICAM1 NCAM1
4 interferon-gamma-mediated signaling pathway GO:0060333 8.62 ICAM1 NCAM1

Molecular functions related to Lethal Midline Granuloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.16 NCAM1 SPTAN1
2 virus receptor activity GO:0001618 8.96 ICAM1 NCAM1
3 signaling receptor activity GO:0038023 8.8 CD2 ICAM1 LILRA3
Sources

Sources for Lethal Midline Granuloma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....